Penumbra (NYSE:PEN) Releases Earnings Results, Beats Expectations By $0.09 EPS

Penumbra (NYSE:PEN - Get Free Report) issued its earnings results on Tuesday. The company reported $0.97 earnings per share for the quarter, beating analysts' consensus estimates of $0.88 by $0.09, Zacks reports. Penumbra had a net margin of 1.17% and a return on equity of 9.74%. The firm had revenue of $315.52 million for the quarter, compared to analyst estimates of $311.63 million. Penumbra updated its FY 2025 guidance to EPS.

Penumbra Stock Down 3.5 %

Shares of NYSE:PEN traded down $10.60 during trading on Friday, reaching $292.52. 635,327 shares of the stock were exchanged, compared to its average volume of 492,793. The stock has a fifty day moving average of $259.09 and a two-hundred day moving average of $227.84. Penumbra has a 1-year low of $148.00 and a 1-year high of $310.00. The company has a debt-to-equity ratio of 0.02, a current ratio of 6.01 and a quick ratio of 3.25. The firm has a market cap of $11.27 billion, a price-to-earnings ratio of 860.35, a price-to-earnings-growth ratio of 2.83 and a beta of 0.53.

Insider Buying and Selling at Penumbra

In related news, CEO Adam Elsesser sold 15,000 shares of the company's stock in a transaction dated Friday, December 20th. The shares were sold at an average price of $242.96, for a total value of $3,644,400.00. Following the sale, the chief executive officer now owns 837,582 shares in the company, valued at $203,498,922.72. This represents a 1.76 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Johanna Roberts sold 600 shares of the stock in a transaction that occurred on Monday, December 2nd. The stock was sold at an average price of $244.49, for a total value of $146,694.00. Following the completion of the sale, the executive vice president now directly owns 63,444 shares of the company's stock, valued at approximately $15,511,423.56. This trade represents a 0.94 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 18,219 shares of company stock worth $4,426,439. 5.00% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on PEN shares. StockNews.com raised Penumbra from a "hold" rating to a "buy" rating in a report on Thursday. Robert W. Baird lifted their price target on Penumbra from $305.00 to $328.00 and gave the company an "outperform" rating in a research note on Wednesday. Oppenheimer assumed coverage on shares of Penumbra in a research report on Tuesday, December 17th. They set an "outperform" rating and a $275.00 target price on the stock. Needham & Company LLC reiterated a "hold" rating on shares of Penumbra in a research report on Wednesday. Finally, JPMorgan Chase & Co. lifted their target price on shares of Penumbra from $230.00 to $285.00 and gave the stock an "overweight" rating in a research report on Wednesday. Three investment analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $292.64.

About Penumbra

Penumbra, Inc, together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.